Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies

M. Ian Phillips, Yao Liang Tang

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

Gene modification of stem cells prior to their transplantation enhances their survival and increases their function in cell therapy. Like the famous Trojan horse, the gene-modified cell has to gain entrance into the host's walls and survive to deliver its transgene products. Using cellular, molecular, and gene manipulation techniques, the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia, and apoptosis. Genetic engineering to modify cells involves construction of functional gene sequences and their insertion into stem cells. The modifications can be simple reporter genes or complex cassettes with gene switches, cell-specific promoters, and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and nonviral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, and hemophilia.

Original languageEnglish (US)
Title of host publicationProgress in Molecular Biology and Translational Science
PublisherElsevier B.V.
Pages285-304
Number of pages20
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Publication series

NameProgress in Molecular Biology and Translational Science
Volume111
ISSN (Print)1877-1173

Fingerprint

Hemophilia A
Stem Cells
Transplantation
Genes
Transgenes
Therapeutics
Switch Genes
Genetic Engineering
Insertional Mutagenesis
Cell- and Tissue-Based Therapy
Reporter Genes
Small Interfering RNA
Cardiovascular Diseases
Apoptosis
Inflammation

Keywords

  • Cre/LoxP
  • Diabetes
  • Heart failure
  • Hemophilia
  • MicroRNA
  • siRNA
  • Vigilant vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Phillips, M. I., & Tang, Y. L. (2012). Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies. In Progress in Molecular Biology and Translational Science (pp. 285-304). (Progress in Molecular Biology and Translational Science; Vol. 111). Elsevier B.V.. https://doi.org/10.1016/B978-0-12-398459-3.00013-7

Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies. / Phillips, M. Ian; Tang, Yao Liang.

Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. p. 285-304 (Progress in Molecular Biology and Translational Science; Vol. 111).

Research output: Chapter in Book/Report/Conference proceedingChapter

Phillips, MI & Tang, YL 2012, Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies. in Progress in Molecular Biology and Translational Science. Progress in Molecular Biology and Translational Science, vol. 111, Elsevier B.V., pp. 285-304. https://doi.org/10.1016/B978-0-12-398459-3.00013-7
Phillips MI, Tang YL. Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies. In Progress in Molecular Biology and Translational Science. Elsevier B.V. 2012. p. 285-304. (Progress in Molecular Biology and Translational Science). https://doi.org/10.1016/B978-0-12-398459-3.00013-7
Phillips, M. Ian ; Tang, Yao Liang. / Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies. Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. pp. 285-304 (Progress in Molecular Biology and Translational Science).
@inbook{df541bc40efe4dbc9b943b08b7778a79,
title = "Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies",
abstract = "Gene modification of stem cells prior to their transplantation enhances their survival and increases their function in cell therapy. Like the famous Trojan horse, the gene-modified cell has to gain entrance into the host's walls and survive to deliver its transgene products. Using cellular, molecular, and gene manipulation techniques, the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia, and apoptosis. Genetic engineering to modify cells involves construction of functional gene sequences and their insertion into stem cells. The modifications can be simple reporter genes or complex cassettes with gene switches, cell-specific promoters, and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and nonviral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, and hemophilia.",
keywords = "Cre/LoxP, Diabetes, Heart failure, Hemophilia, MicroRNA, siRNA, Vigilant vector",
author = "Phillips, {M. Ian} and Tang, {Yao Liang}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-398459-3.00013-7",
language = "English (US)",
series = "Progress in Molecular Biology and Translational Science",
publisher = "Elsevier B.V.",
pages = "285--304",
booktitle = "Progress in Molecular Biology and Translational Science",

}

TY - CHAP

T1 - Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies

AU - Phillips, M. Ian

AU - Tang, Yao Liang

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Gene modification of stem cells prior to their transplantation enhances their survival and increases their function in cell therapy. Like the famous Trojan horse, the gene-modified cell has to gain entrance into the host's walls and survive to deliver its transgene products. Using cellular, molecular, and gene manipulation techniques, the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia, and apoptosis. Genetic engineering to modify cells involves construction of functional gene sequences and their insertion into stem cells. The modifications can be simple reporter genes or complex cassettes with gene switches, cell-specific promoters, and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and nonviral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, and hemophilia.

AB - Gene modification of stem cells prior to their transplantation enhances their survival and increases their function in cell therapy. Like the famous Trojan horse, the gene-modified cell has to gain entrance into the host's walls and survive to deliver its transgene products. Using cellular, molecular, and gene manipulation techniques, the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia, and apoptosis. Genetic engineering to modify cells involves construction of functional gene sequences and their insertion into stem cells. The modifications can be simple reporter genes or complex cassettes with gene switches, cell-specific promoters, and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and nonviral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, and hemophilia.

KW - Cre/LoxP

KW - Diabetes

KW - Heart failure

KW - Hemophilia

KW - MicroRNA

KW - siRNA

KW - Vigilant vector

UR - http://www.scopus.com/inward/record.url?scp=84865346053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865346053&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398459-3.00013-7

DO - 10.1016/B978-0-12-398459-3.00013-7

M3 - Chapter

C2 - 22917236

AN - SCOPUS:84865346053

T3 - Progress in Molecular Biology and Translational Science

SP - 285

EP - 304

BT - Progress in Molecular Biology and Translational Science

PB - Elsevier B.V.

ER -